Page last updated: 2024-11-05

troglitazone and Thyroid Neoplasms

troglitazone has been researched along with Thyroid Neoplasms in 7 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.

Research Excerpts

ExcerptRelevanceReference
"Cotreatment with troglitazone and lovastatin altered the epithelial-to-mesenchymal-transition (EMT) -related marker gene expression of the cells; specifically, E-cadherin expression increased and vimentin expression decreased."1.42Combined treatment with troglitazone and lovastatin inhibited epidermal growth factor-induced migration through the downregulation of cysteine-rich protein 61 in human anaplastic thyroid cancer cells. ( Chin, LH; Hsu, SP; Liang, YC; Zhong, WB, 2015)
"Troglitazone is a potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARgamma) that is a ligand-activated transcription factor regulating cell differentiation and growth."1.33Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. ( Clark, OH; Cotter, P; Duh, QY; Ginzinger, DG; Hyun, WC; Kanauchi, H; Lobo, M; Park, JW; Wong, MG; Zarnegar, R, 2005)
" RS5444 did not induce apoptosis but combined with paclitaxel, doubled the apoptotic index compared to that of paclitaxel."1.33Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. ( Copland, JA; Fujiwara, K; Haugen, BR; Klopper, JP; Kreinest, PA; Kurakata, S; Marlow, LA; Smallridge, RC; Williams, SF; Wong, AK, 2006)
"We used six thyroid cancer cell lines: TPC-1, FTC-133, FTC-236, FTC-238, XTC-1, and ARO82-1."1.32Modulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by chemotherapy in thyroid cancer cell lines. ( Clark, OH; Duh, QY; Hyun, WC; Lobo, M; Park, JW; Wong, MG, 2003)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (71.43)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fröhlich, E2
Wahl, R2
Chin, LH1
Hsu, SP1
Zhong, WB1
Liang, YC1
Park, JW2
Wong, MG2
Lobo, M2
Hyun, WC2
Duh, QY2
Clark, OH2
Zarnegar, R1
Kanauchi, H1
Ginzinger, DG1
Cotter, P1
Machicao, F1
Copland, JA1
Marlow, LA1
Kurakata, S1
Fujiwara, K1
Wong, AK1
Kreinest, PA1
Williams, SF1
Haugen, BR1
Klopper, JP1
Smallridge, RC1
Ohta, K1
Endo, T1
Haraguchi, K1
Hershman, JM1
Onaya, T1

Reviews

1 review available for troglitazone and Thyroid Neoplasms

ArticleYear
The current role of targeted therapies to induce radioiodine uptake in thyroid cancer.
    Cancer treatment reviews, 2014, Volume: 40, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Agents; Chromans; Female; Forecasting; Gene Expression Regulation, Ne

2014

Other Studies

6 other studies available for troglitazone and Thyroid Neoplasms

ArticleYear
Combined treatment with troglitazone and lovastatin inhibited epidermal growth factor-induced migration through the downregulation of cysteine-rich protein 61 in human anaplastic thyroid cancer cells.
    PloS one, 2015, Volume: 10, Issue:3

    Topics: Cell Line, Tumor; Cell Movement; Chromans; Cyclic AMP Response Element-Binding Protein; Cysteine-Ric

2015
Modulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by chemotherapy in thyroid cancer cell lines.
    Thyroid : official journal of the American Thyroid Association, 2003, Volume: 13, Issue:12

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins;

2003
Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines.
    Thyroid : official journal of the American Thyroid Association, 2005, Volume: 15, Issue:3

    Topics: Adenocarcinoma, Follicular; Cell Cycle; Cell Differentiation; Cell Division; Cell Line, Tumor; Chrom

2005
Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture.
    Endocrine-related cancer, 2005, Volume: 12, Issue:2

    Topics: Adenocarcinoma, Follicular; Animals; Annexin A5; Apoptosis; Cell Differentiation; Cell Line, Transfo

2005
Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1.
    Oncogene, 2006, Apr-13, Volume: 25, Issue:16

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc

2006
Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells.
    The Journal of clinical endocrinology and metabolism, 2001, Volume: 86, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Northern; Carcinoma, Papillary; Cell Division;

2001